Molecure S.A. (WSE:MOC)

Poland flag Poland · Delayed Price · Currency is PLN
8.12
-0.16 (-1.93%)
May 23, 2025, 4:35 PM CET
-47.34%
Market Cap 166.07M
Revenue (ttm) 3.49M
Net Income (ttm) -29.63M
Shares Out 20.20M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,691
Average Volume 11,143
Open 8.30
Previous Close 8.28
Day's Range 8.10 - 8.30
52-Week Range 7.60 - 16.70
Beta 2.59
RSI 43.60
Earnings Date Apr 30, 2025

About Molecure

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 102
Stock Exchange Warsaw Stock Exchange
Ticker Symbol MOC
Full Company Profile

Financial Performance

In 2024, Molecure's revenue was 2.92 million, a decrease of -20.08% compared to the previous year's 3.65 million. Losses were -31.29 million, 10.3% more than in 2023.

Financial Statements

News

There is no news available yet.